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Abstract
Cells of the innate and adaptive immune system are key factors in the progression of athero-
sclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute ather-
othrombotic events such as coronary artery disease, cerebrovascular disease and
peripheral arterial disease. Here, we describe the cloning, expression, purification, and
immunoreactivity assessment of a recombinant single-chain variable fragment (scFv)
derived from a human anti-αIIbβ3 antibody (HuAb) selected to target atheromatous lesions
for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to
play a role in inflammation, in platelet-leucocyte aggregates and in thrombi formation and
might thus be considered relevant biomarkers of atherosclerotic progression. The DNA
sequence that encodes the anti-αIIbβ3 TEG4 scFv previously obtained from a phage-dis-
play selection on activated platelets, was inserted into the eukaryote vector (pPICZαA) in
fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experi-
ments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L
culture). The advantage of P. pastoris as an expression system is the production and secre-
tion of recombinant proteins in the supernatant, ruling out the difficulties encountered when
scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity).
The improved conditions allowed for the recovery of highly purified and biologically active
scFv fragments ready to be grafted in a site-directed way to nanoparticles for the imaging of
atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.
Introduction
Atherosclerosis is an inflammatory disease associated with the formation of unstable thrombo-
sis-prone atheroma plaques made of large lipid cores, thin fibrous cap and inflammatory cell
infiltrates within the walls of arteries.[1] Atherosclerotic plaque rupture is the mechanistic
cause of about 75% of all sudden and often fatal heart attacks.[2] As the risk of plaque rupture
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is more related to the plaque contents than to the plaque size, molecular imaging modalities
have risen as a new imperative. Current studies tend towards the development of non-invasive
targeted methods to assess the cellular components that underlie the risk of rupture.[3,4]
Molecular imaging requires highly sensitive and specific probes made of a signal detection
compound and an affinity ligand for targeting. The affinity ligand should be able to recognize
molecules and cells over-expressed during the course of atherogenesis. Inflammation is a well-
recognized pathophysiological process involving both innate and adaptive immune cells.[5]
Recruitment of monocytes in the vascular wall and macrophage differentiation and prolifera-
tion represent a hallmark in the pathology of atherosclerotic lesions.[6] They contribute to the
processes that underlie atherogenesis such as lipid accumulation, secretion of pro-inflamma-
tory cytokines, extracellular matrix remodelling. Moreover, the observation of activation and
oligoclonal expansion of T cells has suggested the presence of inciting antigens (Ags) that sus-
tain T cell recruitment within coronary lesions.[7] B cells also play a pro or anti-atherogenic
role depending on the subtypes (B1(a) or B2), and in atherosclerosis they accumulate both in
the atherosclerotic intima and associated adventitia.[8–10] More recently, platelets have come
to the forefront as partners of macrophages, T cells and B cells in inflammation and immune
responses. They are now recognized as key players in innate and adaptive immune responses
[11,12] and notably shown to modulate the T-effector/T-regulator balance via the CD40
ligand.[13,14] Platelet-derived CD40 ligand has also been reported to support B-cell differenti-
ation and immunoglobulin class switching in mice.[15] Several cytokines released by activated
platelets have been demonstrated to modulate monocyte and macrophage function.[16] More-
over platelet—leukocyte interactions largely contribute to OxLDL uptake and foam cell forma-
tion.[17] A recent study has underlined the presence of platelets not only in thrombi and
intraplaque hemorrhage but also in atheroma burden, around necrotic areas and neovessels,
shedding light on the rationale for targeting platelets within atherosclerotic lesions.[18]
Today, antibodies are used for several applications in research, diagnostics, and therapy.
[19] Technology improvements are focused on several approaches to manufacturing recombi-
nant human antibodies.[20] Moreover, in vitro selection technologies such as antibody phage
display or ribosomal display have accelerated the generation of these recombinant human anti-
bodies.[21–23]
To develop a novel non-invasive targeting approach for atheroma, our team previously
selected, using in vitro phage display biotechnology on activated platelets, a phage-scFv fully
human antibody (HuAb) specific to the αIIbβ3 integrin, which is an integrin only expressed
on platelets and not on other immune cells.[24] This human antibody was further processed as
a whole human IgG4 molecule in baculovirus system.[18] We proved the maintenance of the
bioactivity after grafting onto superparamagnetic nanoparticles dedicated to MRI imaging.
However, the chemical functionalization was hard to proceed, time-consuming and we did
not succeed in grafting more than one HuAb onto each nanoparticle [18]. To overcome these
drawbacks and obtain a better conjugation ratio, another type of protein engineering has been
applied to reduce the probe size. A scFv protein composed of the heavy (VH) and light (VL)
chains of an antibody linked with a flexible peptide, has been constructed by recombinant
DNA technology. The diameter of scFv fragments (5 nm), one-fifth the size of whole IgG, is
more suitable for functionalizing relatively small nanoparticles. Compared to much larger
forms of antibodies such as Fab, Fab’2 and IgG, scFv have lower retention times in non-target
tissues and exhibit more rapid blood clearance and better penetration into targeted lesions.
[25] Moreover, this recombinant form can be generated with tags for purification and site-spe-
cific attachment via engineered thiols to avoid loss of bioactivity. There are a variety of recom-
binant production systems for the generation of scFvs ranging from bacteria, filamentous
fungi, insect cell lines to transgenic plants.[20,26] More specifically, studies reported the
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production of an anti-platelets scFv antibody in transient mammalian cells system (e.g, free-
style HEK 293F cells).[26] However, transient antibody production appears more suitable for
small-scale production in antibody screening. Here, TEG4 HuAb needs to be stably expressed
as scFv fragments in a quantity so that purification, characterization and further grafting of
isolated recombinant fragments could be readily accomplished. Hence, TEG4 HuAb was pro-
cessed in Pichia pastoris. The choice of production in yeast cells was guided by previous experi-
ments where biological activity could only be recovered in the cytoplasm of cells when using E.
coli as a host expression system. Indeed, despite improvements in fedbatch fermentation pro-
duction, a proportion of inactive scFv remained in the total purified population.[27] From this
point of view, the Pichia pastoris expression system is an attractive way due to its ability to
secrete a large amount of recombinant protein in the supernatant, thereby facilitating the puri-
fication steps.
The aim of the study was thus to produce highly purified and biologically active scFv frag-
ments in a suitable yeast cell expression modality. The biochemical characteristics of the anti-
αIIbβ3 scFv were evaluated by ELISA, affinity binding analyses, flow cytometry against plate-
lets and immunohistochemistry (IHC) on atheroma plaques from animal models and human
coronary sections. These scFv fragments are ready to be grafted in a site-directed way to nano-
particles for the imaging of atherosclerotic plaques where inflammatory and immune pro-
cesses increase the risk of instability.
Materials and Methods
Materials
Large-scale expression of TEG4-2c scFv in Pichia pastoris was carried out in BIOSTAT Bplus
laboratory fermentor 5L (Sartorius-Stedim Biotech, Germany). Data and set points were moni-
tored with MFCS-Win. Growth media were purchased from Becton Dickinson (Le Pont de
Claix, France).
Immobilized Metal Affinity Chromatography (IMAC) was carried out on HisTrap™ excel
column (id 5 mL, GE Healthcare, Sweden) containing resin charged with nickel ions. Buffers
for chromatographic runs, and reagents were prepared using chemicals of analytical grade
from Sigma-Aldrich (Saint Quentin Fallavier, France).
Chromatographic experiments were performed using A¨KTA pilot workstation (GE Health-
care) and were monitored with Unicorn 5.1 software. Protein detection was monitored at 215
and 280 nm.
Spectrophotometric measurements of samples drawn from the fermentor and BCA protein
assay measurements were carried out using SAFAS UVmc2 double-beam UV-visible spectro-
photometer (Socie´te´ Anonyme de Fabrication d’Appareillages Scientifiques, Monaco). Flow
cytometry experiments were performed on a FACSCanto I cytometer from BD Biosciences
(Le Pont de Claix, France) and monitored using DIVA software.
The absorbance of ELISA assays was read at 405 nm using a CHAMELEON microplate
reader from ScienceTec (Les Ulis, France).
Surface Plasmon Resonance (SPR) experiments on purified αIIbβ3 integrin (Kordia Life
Sciences, Leiden, The Netherlands) were carried out using the BIAcoreTM 3000 (GE Health-
care Europe GmbH, Velizy-Villacoublay, France) equipped with research-grade CM5 sensor
chips. Bio-Layer Interferometry (BLI) experiments on lyophilized platelets (Helena Biosci-
ences Europe, Queensway S, UK) were performed using an Octet instrument (Octet Red96
Pall Life Sciences, Saint-Germain-en-Laye, France) and HIS2 (anti-penta Histidine Ab)
sensors.
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Methods
1-Vectors and Strains. The pHOG21 vector, kindly provided by M. Little (Affimed Ther-
apeutics, Lademburg, Germany), pCR4-TOPO and pPICZαA (Invitrogen, Carlsbad, USA)
plasmids were used for preparation of DNA constructs. Synthetic oligonucleotides were pur-
chased at Eurogentec (Liege, Belgium). Cloning step was carried out with Escherichia coli strain
JM109 (NewEnglands Biolabs, Ipswich, MA USA). Pichia pastoris strain X33 used for produc-
tion of recombinant TEG4-2c scFv was obtained from Invitrogen (Carlsbad, CA, USA).
2-Construction of an expression vector for TEG4-2c scFv. The TEG4 scFv DNA frag-
ment provided in the pHOG21 vector previously used for the TEG4 scFv expression in
XL1-Blue E. coli [16] was used as template to generate a new scFv format containing 2 cysteines
into the C-terminal end. The coding sequence was PCR-amplified with Pfu Turbo polymerase
(Stratagene). The primers (PICTE: 5’-TATCACGTGGCAGGTGCAGCTGGTGG-3’ and
PIC2C: 5’-TCTAGATTAGCAGCACCCGTGATGGTGATGGTG-3’) were used to introduce the
6HisTag- Gly-Cyc-Cys-Stop amino acid sequence. Thirty amplification cycles were performed
(30s at 95˚C, 45s at 48˚C and 1min at 72˚C) followed by a final extension of 10 min at 72˚C.
The PCR product was purified, ligated into pCR4-TOPO plasmid and verified by DNA
sequencing (Millegen Technology—France). The resultant plasmid was digested by PmlI and
XbaI to excise TEG4-6His-Gly-Cys-Cys DNA fragment and ligated into the expression vector
pPICZαA (Invitrogen, Carlsbad, USA) containing the Zeocin resistance gene for selection and
the AOX1 promoter. The new construction of TEG4-2c scFv is shown in Fig 1.
The resultant plasmid was linearized by PmeI and transformed into competent P. pastoris
X-33 cells by electroporation using Gene Pulser II (Bio-Rad, Hercules, CA, USA). Transfor-
mant cells were grown on YPDS-Zeocin 150 μg/mL-agar plates and screened again later for
their ability to grow on Zeocin (Invitrogen, Carlsbad, USA) up to concentrations of 2 mg/ml.
Fig 1. pPICZαA expression vector according to the EasySelect Pichia Expression Kit Manual (Invitrogen) and a schematic
representation of TEG4-2c scFv with the protein sequence. (A): All the featured restriction sites are unique. 5´ AOX1: promoter region of
AOX1; TT AOX1: transcription termination of AOX1; PTEF1: promoter of TEF1; PEM7: promoter of EM7; Zeocin resistance: Sh ble ORF;
CYC1 TT: transcription termination of CYC1. (B): The TEG4-2c scFv coding sequence was cloned between PmlI and XbaI sites and the
protein sequence of recombinant tag-scFv including the 6His-tag and the 2 cysteine are highlighted in green. The α-factor signal sequence is
represented in blue and the C-myc tag is highlighted in yellow.
doi:10.1371/journal.pone.0170305.g001
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Selected clones were tested for the presence of TEG4-2c scFv coding sequence in their genome
by colony PCR analysis using the PICTE and PIC2C primers, amplification cycles were pre-
ceded by a heating step 3 min at 95˚C.
3-Expression and purification of TEG4-2c scFv. Transformed P. pastoris cells that exhib-
ited high resistance to Zeocin (up to 2 mg/mL plates) were grown in shake flasks containing
100 ml of buffered glycerol complex medium (BMGY, 1% yeast extract, 2% peptone, 100 mM
potassium phosphate buffer at pH 6.0, 13.4g/L YNB, 4x10-4 g/L biotin, 10 g/L glycerol and
150 μg/mL Zeocin) until an optical density of 20 was reached. The culture was inoculated in a
5L bioreactor at 0.2 OD units. The bioreactor conditions were optimized by modification of
Narasimhan, J et al.[28] The temperature and pH were maintained at 30˚C and 6 respectively,
and dissolved oxygen levels were maintained at 20% saturation by regulating aeration and agi-
tation in a cascading system. After complete consumption of glycerol in the medium (20 to 24
hours), a methanol fed-batch phase was initiated by adding methanol every 12 h to a final con-
centration of 0.6%; this phase promotes the induction of scFv production and secretion in the
medium. The methanol feed frequency was modified to every 6 h during the 4 latest days of
production. Samples were drawn every 24 h to determine the yeast growth profile and scFv
production. After 120 h of induction, the culture was harvested and the supernatant frozen at
-80˚C pending purification steps. Prior to purification, the pH of the broth was adjusted to 7.4
and filtered through a 0.45 μm cellulose acetate membrane.
The expressed recombinant TEG4-2c scFv was purified using IMAC. The HisTrap Excel
resin was equilibrated with 50 mM Tris-HCl pH 7.5, 500 mM NaCl (buffer A at a flow rate of 3
mL/min). Typically, 450 to 800 mL P. pastoris expression broth supernatant containing the
scFv was directly injected into the column. The column was then washed with buffer A until
absorbance at 280nm reached the baseline. The elution was carried out into two steps using
5% and 30% buffer B (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 500 mM imidazole) corre-
sponding respectively to 25 mM and 150 mM imidazole. The elution fraction was dialyzed
against PBS (NaCl 135 mM, KCl 2.5 mM, Na2HPO4 10 mM, KH2PO4 1.5 mM pH 7.4) buffer.
4-Protein assay, SDS-PAGE and Dot-blot analysis. Protein quantification of the chro-
matographic fractions was performed using bicinchoninic acid protein micro-assay (BCA kit,
Sigma). Twenty-five microliters samples were incubated with 200 μL of BCA working reagent
and plate was incubated at 37˚C for 30 min. The absorbance was measured at 562 nm.
Fractions obtained from chromatographic experiments were analyzed by SDS-PAGE under
reducing conditions over 12% polyacrylamide gels. Supernatant and flow through fractions
were 5x concentrated by TCA precipitation. Precision plus protein prestained standards
(BIO-RAD) were used as molecular weight ladder.
To analyse the efficiency of the yeast cells P. pastoris to produce the scFv fragments into the
broth medium, 50 μL samples from day 1 to day 5 were blotted on a nitrocellulose membrane
using Bio-Dot Microfiltration Instrument (BIO-RAD). The membrane was blocked with a
blocking buffer (TBS Tween with 3% milk powder) for 2 hours. The membrane was again
washed twice with TBS-tween, and then incubated with primary antibody (Anti 6His,
SIGMA) at 1:1500 dilution overnight at 4˚C. Membranes were then washed and probed with a
secondary antibody (anti-mouse IgG-HRP Cell Signaling Technology) at 1:5000 dilution.
Colorimetric analysis was performed using Opti4CN (BIO-RAD) kit by gently shaking
until color develops.
5-Preparation of Platelet-Rich-Plasma (PRP) and washed platelets. Platelet-rich plasma
(PRP) and washed platelets were prepared from the blood of voluntary healthy donors.
PRP was obtained from venous blood anticoagulated with sodium citrate (0.38%, w/v) after
centrifugation at 120 g for 10 min at room temperature.[29]
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For the preparation of washed platelets, venous blood was anticoagulated with citric acid-
citrate-dextrose NIH formula A (ACD-A) (1 vol of anticoagulant: 6 vol of blood). After centri-
fugation at 120 g for 10 min, the PRP was collected and mixed with ACD-A (1 vol: 9 vol, PRP)
plus 100 nM prostaglandin E1 and 0.05 U/mL Apyrase
Grade7,[30] Platelets were sedimented by
centrifugation at 1100 g for 15 min, washed and adjusted at 108/mL in a modified Tyrode’s
buffer (137 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.3 mM NaH2PO4, 1 mM MgCl2, 5.5
mM glucose, 5 mM HEPES, 0.1% (wt/vol) bovine serum albumin (BSA), pH 7.4.
6-Analysis of TEG4-2c scFv reactivity by Flow cytometry.
Analysis on washed platelets
For the analysis of TEG4-2c scFv reactivity on platelets, washed platelets were activated
with 0.5 U/ml human α-thrombin (Fibrindex, Ortho-Diagnostics, Raritan, NJ). Samples of
both activated and non-activated platelets were fixed for 30 min with an equal volume of para-
formaldehyde (PFA) 2% and then incubated with diluted TEG4-2c scFv.
Aliquots of 108 PFA-fixed-washed-platelets/mL (10 μL) [27] non-activated (NA-PL) or acti-
vated with thrombin (A-PL) were incubated with 25 μg/mL of TEG4-2c scFv human antibody
or PAC-1 commercial IgM antibody (BD Biosciences) [31] targeting the activated αIIbβ3
integrin overnight at 4˚C. After two washes in PBS, a 30 min incubation with secondary Alexa
Fluor 488 anti-6His or goat anti-mouse IgM antibodies (1:20) was performed for detection of
respectively, the TEG4-2c scFv and the murine PAC-1 antibody. Reactions in the absence of
antibodies were used as negative controls.
Analysis on PRP samples
Aliquots of 4 μL of PRP are used in each experiment. Some aliquots are activated with
50 μM thrombin receptor activating peptide (TRAP6; Sigma Aldrich, Saint-Quentin-Fallavier,
France). Activated (+TRAP) and non-activated PRP aliquots (-TRAP) were then incubated
with diluted TEG4-2c scFv (25 μg/ml) 15 min before adding secondary Alexa Fluor 488 anti-
6His (both 1:20) antibody for another 15 min incubation. Reactions in the absence of antibod-
ies were used as negative controls.
Cells were then resuspended in PBS before analysis on the FACSCanto I cytometer. The
forward and wide-angle light scattering and fluorescence intensity from 10,000 platelets were
collected using a logarithmic gain.
7-Analysis of TEG4-2c scFv reactivity by ELISA. A 96-well flat-bottom polystyrene
microtiter plate (Costar, Corning, NY) was coated with washed thrombin-activated (A-PL) or
non-activated platelets (NA-PL) at 107 platelets/well or BSA protein 20 μg/mL (Sigma-Aldrich)
in 50 mM carbonate-bicarbonate buffer (pH 9.6) overnight at 4˚C. The plate was washed three
times with PBS (pH 7.4) containing 0.05% Tween 20 (200 μL/well) and blocked with 5%
skimmed milk in PBS for 2 h at 37˚C. TEG4-2c scFv fragments purified by IMAC or full-length
mouse IgG antibody (AP2 antibody targeting αIIbβ3 integrin) [32] were tested on A-PL and
NA-PL. After incubation for 2 h at 20˚C, the plate was washed and incubated with an anti-
6His IgG antibody (GE Healthcare) for 1 h at 37˚C to detect scFv fragments or with PBS for
full-length mouse antibodies. After washings, 100 μL of a 1:1000 dilution of horseradish perox-
idase (HRP)-conjugated anti-mouse IgG (Immunotech, Marseille, France) was added and
incubated for 90 min at room temperature. Color was developed with 100 μL of 2;2’-Azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) (Sigma-Aldrich, Saint-Quentin, Fallavier,
France) and the absorbance was read at 405 nm using a CHAMELEON microplate reader.
8-Preparation of atheromatous and healthy aorta proteins. All animal experiments
were performed in conformity with the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85–23, revised 1996) and were accredited by the local ethical committee.
Adult male New Zealand rabbits (NZW), weighting from 2.5 kg to 3.0 kg, were obtained
from Charles Rivers Laboratories (St Germain sur l’Arbresle, France).
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In order to mimic atherosclerosis that develop in humans, rabbits were fed a fat atherogenic
diet including 0.3% cholesterol for 8 months and were subjected to surgeries to allow the for-
mation of complex plaques with intramural thrombi. A first surgery was performed to remove
endothelial cells from the thoracic until the abdominal aorta using a Fogarty catheter (Fogarty
4F; Edwards Lifesciences). The second surgery consists in an angioplasty using an expandable
latex balloon (Maxxum, Boston Scientific; 20 mm long, diameter of 4.5 mm) under radioscopic
guidance from the region of renal arteries to iliac bifurcation. Surgeries were performed under
anesthesia by intramuscular administration of 20 mg/kg ketamine and 2 mg/kg xylazin. Anaes-
thesia was maintained with isoflurane gas (0.25% to 0.35%). As a preventive anti-thrombotic
treatment, 1000 μI of heparine (He´parine Choay, Sanofi Synthe´labo) was infused. After surgery
100 mg aspirine (Aspe´gic injectable, Sanofi Synthe´labo) was administered as analgesia. Aortas
from untreated rabbits and balloon-injured aortas from hypercholesterolemic rabbits were
extracted from the aortic arch to the iliac bifurcation, washed and fractioned in order to solu-
bilize tissue proteins in T-PER (Thermo Fisher Scientific) or HSB (50 mM HEPES, pH 7.4; 137
mM NaCl; 1% NP-40 (v/v); 2 mM EDTA; 1 mM PMSF; protease inhibitors cocktail (Roche
Diagnostics, Meylan, France) lysis buffer. Homogenization was performed using first a Poly-
tron TP-20 Homogenizer (Kinematica, Lucerne, Switzerland) and then a sonicator (3 x 10-sec-
onds pulses at 80% magnitude). After two centrifugations at 13000 g for 45 min at 4˚C to
remove insoluble material from the supernatant, the protein concentration of every soluble
extract was determined using the Bradford assay kit according to the manufacturer’s instruc-
tions (Thermo Fisher Scientific).
9-Affinity determination evaluated by SPR. The interactions between the anti-αIIbβ3
TEG4-2c scFv and the integrin αIIbβ3 were analyzed by SPR sensing using BiacoreTM 3000
(GE Healthcare), according to the manufacturer’s instructions. HBS-EP buffer (0.01 M HEPES
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20) (GE healthcare life sciences,
France) with 2 mM Ca2+ was used as a running buffer. The purified αIIbβ3 was first dialysed
in the running buffer, diluted in 10 mM Na-Acetate, pH 5.5, then immobilized onto the sensor
surface of a Biacore sensor chip CM5 to an immobilized ligand density (RU) of about 8000,
using an amine coupling kit. Then, anti-αIIbβ3 TEG4-2c scFv diluted into the running buffer
at concentrations ranging from 90 to 400 nM was allowed to flow through the sensor chip for
5 min at a flow rate of 20 μL/min and dissociation of bound analyte was allowed to proceed for
15 min before chip regeneration with NaOH 20mM.
10-Affinity determination evaluated by BLI: Octet Red96. Octet instrument is a label-
free detection system that exploits optical principle to read bimolecular interactions, the bio-
layer interferometry (BLI). The interactions between the anti-αIIbβ3 TEG4-2c scFv and blood
platelets were analyzed using Octet (Red96) in platelet buffer (NaCl 137 mM, KCl 2 mM,
NaH2PO4 0.3 mM, MgCl2 1 mM, Glucose 5.5 mM, Hepes 5 mM, Bicarbonate-Na 12 mM
pH6). The purified TEG4-2c scFv was loaded on a HIS2 biosensor (anti-penta Histidine Ab
optical fiber based sensor) at 21 μg/mL. Platelets were diluted in PBS, coated into 96 well plate
and analyzed at different concentrations: 5x105 to 5x108/mL, corresponding to integrin αIIbβ3
molarities from 42 pM to 42 nM. The plate is shaken during reading to create an “orbital
flow”. Controls with no scFv and no platelets were performed to check for nonspecific binding
and signal drift, respectively.
11-Immunohistochemistry Analysis on Murine and Human Atherosclerotic Sections.
All animal studies were approved under the N˚50120192-A by the Animal Care and Use Com-
mittee of Bordeaux, France. The studies were performed in accordance with the ethical stan-
dards laid down in the declaration of Helsinki. ApoE-/- mice were fed a high-cholesterol diet
for 21 weeks to allow for the development of atherosclerotic lesions, afterward they were termi-
nally anaesthetized using a lethal dose of isoflurane. The chest was opened and the aorta
Production of Human scFv Antibody for Atheroma Targeting
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retrieved from the aortic arch to the iliac bifurcation. The lesions-rich areas were subsequently
isolated, fixed and embedded in paraffin. New Zealand white rabbits were prepared as
described in Methods, section 8.
Human coronary arteries were harvested from patients with end-stage heart failure having
undergone heart transplantation. All of the clinical interventions took place at Haut-Le´vèque
Hospital (Pessac, France). All work with tissues from human subjects had been approved by
the CPP committee (Comite´ de Protection des Personnes Sud-Ouest et Outre Mer) of Bor-
deaux and from the Research Ministry in France (Authorization number DC -2016- 2724).
The CPP committee waived the need for patient written consent because surgical waste no lon-
ger attached to the person is considered "RES NULLIUS ". Patients were informed by the clini-
cians; if they did not express their opposition to research, the de-identified samples were
immediately processed and embedded in paraffin.
Paraffin-embedded sections of arterial tissue from mouse, rabbit or human were used in
IHC experiments. The following antibodies were tested on sections from each specie: TEG4-2c
scFv (human fragment antibody, tested between 20 and 40 μg/ml), anti-CD41 (anti-αIIb rabbit
antibody, working dilution 1:200, Abcam, France), AP2 (anti-αIIbβ3 mouse antibody, 10 μg/
mL), RAM11 (mouse antibody, working dilution 1:50) and PGM1 (mouse antibody, working
dilution 10ug/ml) anti-CD68 antibodies targeting rabbit and human macrophages respectively
(Dako, Les Ulis, France).
Paraffin-embedded sections were deparaffinised, rehydrated, and heat mediated antigen
retrieval was performed with Tris-EDTA pH 9 buffer following the specifications of Abcam,
Paris, France (www.abcam.com/ps/pdf/protocols/ihc_p.pdf). Endogenous peroxidase was
then blocked with 3% H2O2 in water, for 15 min. After washing in PBS 1X + 0.025% Triton
(PBST), nonspecific binding was blocked with PBS 1X + 0.2% Triton + 2% bovine serum albu-
min (BSA) for 1 h at room temperature.
Afterwards, antibodies were applied overnight at 4˚C, diluted at 20 μg/mL in PBS 1X + 1%
BSA. The following day, three washes with PBST were performed. To detect TEG4-2c scFv
fragments, an HRP-conjugated antibody specific to 6His (working dilutions 1:250) was applied
to the sections for 1 h at room temperature. HRP-conjugated secondary antibodies specific
to (1) rabbit IgG H+L (Beckman Coulter), (2) mouse IgG H+L (Beckman Coulter) were
respectively applied for commercial primary (1) anti-CD41, (2) RAM-11, PGM1 and AP2
antibodies.
After a further three washes with PBST, staining was performed by adding the peroxidase
substrate diaminobenzidine (DAB substrate kit, Eurobio/ABCys, Les Ulis, France) with H2O2.
It yielded a yellow brown deposit within 10 min at room temperature. After a wash in dH2O to
stop the enzymatic reaction, slides were counterstained in hematoxylin, dehydrated and
mounted.
Results
1-Monitoring TEG4-2c scFv large scale production in Pichia pastoris
After the transformation of P. pastoris with linear pPICZαA-TEG4-2c plasmid, up to 60 clones
were selected on 2 mg/mL Zeocin agar plates. The colony PCR analysis confirmed the presence
of TEG4-2c scFv gene in 16 tested clones. Six clones were evaluated for their capacity to pro-
duce and secrete TEG4-2c scFv in a shake flask. Finally, the clone TEG4-2c A2 was selected for
further analysis and the production scaled up in a 5 L benchtop bioreactor.
Five culture batches were carried out on a 5 L benchtop bioreactor and exhibited a similar
growth profile (data not shown). The culture conditions were maintained as described in the
experimental section. The dissolved oxygen level was maintained throughout the production
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batch at 20% by a combination of agitation and aeration systems, in a cascading manner to
improve the oxygen supply during the growth of cells (Fig 2A). The yeast growth was exponen-
tial during the batch culture with glycerol as the substrate; the glycerol was exhausted after 20
to 24 h culture and the cell density reached 28 OD units corresponding to 8.1 g/L (dry weight).
A fed-batch phase was initiated by adding methanol every 12 h to induce the scFv produc-
tion. To optimize the efficiency of scFv production during the 4 last days, the methanol feed
frequency was every 6 h. Following each substrate addition event, there was a sharp increase in
agitation indicating the active consumption of substrate and sustainable growth of cells. Stir-
ring, which again diminished upon substrate consumption, was raised following the consecu-
tive methanol injection. During the fed-batch phase, a linear increase in yeast biomass was
observed 24 h after induction. A growth rate of 0.23 g L-1h-1 was maintained during 5 days; the
cell density was also increased by a 4.3 fold and reached 35 g/L (dry weight).
Dot-blot analysis was performed to evaluate the TEG4-2c scFv expression each day after
induction in the culture broth. Recombinant TEG4-2c was only produced upon induction of
transformed X-33 cells with methanol. This was clearly confirmed by the absence of signal into
the samples before methanol feeding and into the samples from X33 Pichia cells transfected
with the empty pPICZαA plasmid. The anti-αIIbβ3 TEG4-2c scFv was expressed from the first
day in a soluble form into the cells culture medium (Fig 2B).
2-Purification of TEG4-2c scFv by IMAC
For the purification of recombinant TEG4-2c scFv, optimal performance was obtained when
an intermediate washing step with 25 mM imidazole was used to remove the contaminating
proteins weakly bound to the column, after which recombinant TEG4-2c scFv was eluted
using 150 mM imidazole (Fig 3A).
Typically, 30 mg of TEG4-2c scFv were produced and secreted by P. pastoris into 1L broth
medium after 5 days of growth. The scFv content into this supernatant was estimated to 1.4%
Fig 2. TEG4-2c scFv production process. A: Fed batch fermentation history plot. Stirring, pO2 and OD600 values are plotted versus
time during the cultivation of P. pastoris in BMGY medium. Cultures were induced with methanol at t = 0 (24 h after starting the batch
phase) during the fed batch phase the methanol was added every 12 h or 6h (black arrows) to a final concentration of 0.6%. The average
values are shown with error bars representing the standard deviation (n = 5). 1 OD600 unit was equivalent to 0.29 mg/mL dry weight. B:
Dot-blot analysis of supernatants from recombinant P. pastoris culture. Fifty microliters samples from non-induced culture (NI) and
from day 1 to day 5 induced cultures (I1d to I5d) were undiluted (a) or diluted (b = 1:10; c = 1:50) and blotted on a nitrocellulose
membrane. The recombinant TEG4-2c scFv were detected with the Anti-6His antibody and revealed by colorimetric analysis.
doi:10.1371/journal.pone.0170305.g002
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of the total proteins. After the IMAC purification, the yield was around 22 mg TEG4-2c scFv
from 1L culture medium. This represents a recovery of 70% of produced scFv with a high
purity (> to 80%). This one step chromatography led to a 57 fold purer product with highly
concentrated solution of TEG4-2c scFv (Table 1).
The eluted fractions were analyzed by SDS-PAGE (Fig 3B), which revealed a major band of
35 kDa from the elution step fractions, corresponding to the expected molecular mass of
recombinant TEG4-2c scFv. A weaker band of 75 kDa was also present in this lane, but the
mass spectroscopy analysis revealed that TEG4-2c scFv was the major protein present in this
fraction (data not shown). This data strongly suggests that the higher molecular weight protein
was indeed TEG4-2c scFv dimer.
The elution fraction was dialyzed against PBS buffer. The SDS-PAGE (Fig 3B-EPBS) shows
the purified TEG4-2c scFv as a single thick band with an estimated purity higher than 80%.
The profile of TEG4-2c scFv into PBS buffer (used for ELISA and affinity measurement) is
Fig 3. Purification of recombinant TEG4-2c scFv A: IMAC chromatogram. The HisTrap Excel resin (5 mL) was equilibrated with 50
mM Tris-HCl pH 7.5, 500 mM NaCl (buffer A at a flow rate of 3 mL/min). Pichia pastoris expression broth supernatant containing the
TEG4-2c scFv was injected into the column. The column was then washed with buffer A until absorbance at 280nm reached the
baseline. (Dot Line): The elution was carried out in two steps using 5% and 30% buffer B (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 500
mM imidazole) corresponding respectively to 25 mM and 150 mM imidazole. B: Electrophoretic analysis of one step IMAC
purification of recombinant TEG4-2c scFv. 12% SDS-PAGE stained with colloidal blue, MW: molecular weight ladder (KDa). [S]: 5x
concentrated culture supernatant. [TF]: 5x concentrated flow-through. W: 25 mM imidazole washing fraction. E: 150 mM elution fraction.
EPBS: Elution fraction dialyzed against PBS.
doi:10.1371/journal.pone.0170305.g003
Table 1. IMAC Purification of scFv TEG4-2c produced and secreted by P. pastoris. Data are standardized for 1 L culture media; the values are the
mean of 7 independent experiments ± SD values.
Proteina (mg/mL) scFvb (μg/mL) Volume (mL) Total proteina (mg) Total scFvab (mg) Step recovery (%) Step purification
(fold)
Supernatant 2.190 ± 0.367 30.7 ± 4.3 1000 2190 ± 367 30.7 ± 4.3 100 0
Flow
through
1.983 ± 0.377 ND 1000 1983 ± 377 ND ND ND
Wash step 0.167 ± 0.036 16.7 ± 3.3 75 ± 5 12.53 ± 1.64 1.253 ± 0.25 ND ND
Elution step 0.866 ± 0.136 695 ± 35 31 ± 2 26.85 ± 1.52 21.56 ± 3.01 70.3 ± 0.6 57.35
a Protein concentration was determined by BCA protein assay, using bovine serum albumin as standard.
b,cTEG4-2c scFv into the supernatant and the purity was estimated by densitometric quantification of corresponding lane of SDS-PAGE 12% acrylamide gel
stained by colloidal blue, thanks to Bio-Rad Image Lab™.
ND: not determined.
doi:10.1371/journal.pone.0170305.t001
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similar to the elution fraction (E) obtained at the end of IMAC. The final overall yield of
TEG4-2c was 0.7 mg/mL; it represents 70% of initial product. However, upon SDS-PAGE
analysis, it was observed that some amount of our protein of interest was also lost in the flow-
through and washing steps.
3-Analysis of TEG4-2c scFv binding to platelets by flow cytometry and
ELISA tests
3.1-Flow cytometry analysis using TEG4-2c scFv. Flow cytometry analysis showed a bet-
ter recognition of washed activated platelets versus non-activated ones (Fig 4A). PAC-1, an
IgM murine antibody specific to the activated conformation of αIIbβ3 was included as a posi-
tive control of the experiment. The slight recognition of resting platelets might be due to their
activation during the purification process. Activation of platelets is a problem classically
encountered during their handling and processing. To minimize manipulation steps, the bind-
ing specificity of TEG4-2c scFv was checked on platelets within plasma (analysis on PRP). The
results (Fig 4B) highlighted a binding specificity for platelets activated in PRP with TRAP pep-
tide whereas resting platelets were not recognized.
3.2-ELISA tests. The reactivity of TEG4-2c scFv produced in Pichia pastoris was then
measured on human thrombin-activated and non-activated platelets and on purified αIIbβ3
by ELISA (Fig 4C). We have to underline that, here again, the coating of platelets on ELISA
wells may itself induce their activation. However, a better recognition of activated platelets is
reported with TEG4-2c scFv, especially when using lower concentrations. AP2, a murine anti-
body directed against αIIbβ3 was included as a positive control of the experiment.
4-Binding of scFv TEG4-2c to αIIbβ3 investigated by SPR and BLI
Affinity of TEG4-2c scFv was determined either by surface plasmon resonance (SPR) with a
BIACORE device on purified αIIbβ3 or using the Bio-Layer Interferometry (BLI) technology
with an OCTET instrument on lyophilized platelets resuspended from a freeze-dried solution.
4.1-BIACORE analysis. In this first experimental session using SPR technology, TEG4-2c
scFv was injected at 3, 6 and 12,5 μg/ml on immobilized αIIbβ3, corresponding respectively to
94, 188 and 390 nM. The binding was concentration-dependent (Fig 5A) but the three sensor-
grams could not be fitted using the simple Langmuir model, likely because of the presence of a
more complex interaction, implying monomers and dimers in the purified fractions.
4.2-Binding by BLI. This second set of experiments performed using the Octet instru-
ment aimed at determining the interactions between TEG4-2c scFv and blood platelets (Fig
5B). This is more informative because this strategy allows evaluating the binding on αIIbβ3 in
its natural conformation. TEG4-2c scFv immobilized through an anti-6His coating on an opti-
cal fiber based sensor was immersed in a solution of platelets (seven different concentrations
were used) contained in the well of a 96- well plate. The plate is shaken during reading to cre-
ate an "orbital flow". The different platelet concentrations, from 5x105 to 5x108/ml, were con-
verted into integrin αIIbβ3 molarities by taking into account the number of αIIbβ3 per platelet
(50 000). Controls with no scFv allowed checking for non-specific binding of the platelets on
the sensors. These controls were subtracted from the curves obtained with TEG4-2c scFv.
Other controls were also performed with no platelets (only buffer), assessing the signal drift
due to the potential release of scFv from sensors.
Octet experiments showed good interactions between TEG4-2c scFv and platelets at nano-
molar concentrations superior to 0.4 nM. No Kd could be calculated because no dissociation
was observed. However, considering the binding at 0.8 and 4 nM, the affinity should be in the
nanomolar range.
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Fig 4. Binding assessment of TEG4-2c scFv to human platelets by flow cytometry and ELISA tests. A:
Binding of TEG4-2c scFv on thrombin-activated human (A-PL) or non-activated—platelets (NA-PL) analysed
by flow cytometry. PAC-1 IgM murine antibody serves as a positive control. Binding of antibody to the
platelets was further detected by incubation with Alexa Fluor 488 anti-6His or anti-mouse IgM antibodies.
Negative controls were secondary antibody only. Histograms depict representative data ± SD of three
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5-Evaluation of atheroma burden recognition by IHC and ELISA tests
As the final aim of the project is to target platelets colonizing the plaque, we evaluated the abil-
ity of TEG4-2c scFv to recognize platelets within aorta lesional sections of animal models of
atherosclerosis as well as aorta sections recovered from human coronary specimens (Fig 6A).
The reactivity was also tested on proteins isolated from the extracted aorta from atheromatous
and healthy rabbits by ELISA (Fig 6B).
5.1-IHC. The immunohistochemistry data were in accordance with ELISA with a huge
recognition of platelets in all analyzed sections (Fig 6A). An antibody directed against murine
αIIb (anti-CD41) and antibodies directed against rabbit and human macrophages (anti-CD68)
over-expressed in the atheroma burden were included as positive controls. We also compared
the targeting of TEG4-2c scFv with that of AP2, an antibody we have already demonstrated
able to label mouse, rabbit and human platelets.
5.2-ELISA tests. ELISA assay clearly showed a better recognition of atheromatous pro-
teins with TEG4-2c scFv and AP2 antibodies (Fig 6B). An anti-CD68 macrophage rabbit anti-
body was included as positive control. We confirmed by mass spectroscopy analysis (data not
shown) that the αIIbβ3 integrin is also present in healthy aorta but to a lesser extent.
independent experiments. Quantitative fluorescence intensities (in Geo mean) are stated under each
respective histogram. B: Binding of TEG4-2c scFv on TRAP-activated-human (+ TRAP) or non-activated
platelets (-TRAP) analysed by flow cytometry. Quantitative fluorescence intensities (in Geo mean) are stated
under each respective histogram. C: Representative whole cell (A-PL, NA-PL) and purified proteins (αIIbβ3,
BSA) ELISA with TEG4-2c scFv. A murine anti-αIIbβ3 antibody AP2 was used as positive control. Negative
controls were secondary antibody only. Binding of antibodies was visualized via HRP-6His or HRP-anti-
mouse IgG. OD value represents absorbance at 450 nm. Plots represent the mean values ± SD (n = 3)
doi:10.1371/journal.pone.0170305.g004
Fig 5. Binding of scFv TEG4-2c to αIIbβ3 by SPR and to whole platelets by BLI. A: SPR sensorgrams. The ligand αIIbβ3 was
immobilized on CM5 chip by amine coupling with a density of 8000 RU. Serial dilutions of TEG4-2c in HBS-EP running buffer were injected
over the ligand corresponding to 94, 188 and 390 nM. Sensorgrams show a binding concentration-dependent of TEG4-2c scFv. B: BLI
analysis. TEG4-2c scFv (ligand) was loaded on HIS2 biosensor (anti-penta Histidine Ab) at 21 μg/mL. Whole platelets (analyte)
concentrations converted into αIIbβ3 molarities were: 41.5, 8.3, 4.15, 0.83, 0.415, 0.083 and 0.0415 nM. Additionally one sensor pair was
used to record the buffer reference signals. TEG4-2c scFv reacts with αIIbβ3 in its natural conformation in a concentration dependent
manner.
doi:10.1371/journal.pone.0170305.g005
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Fig 6. Comparison of the immunoreactivity of TEG4-2c scFv to atherosclerotic tissues of different species by IHC analysis
and ELISA assays. A (a-r): IHC assays on atherosclerotic tissues: similarly to positive controls e.g; anti-CD41 (anti-αIIb) (e), RAM11
and PGM1 (anti-CD68 antibodies targeting rabbit and human macrophages respectively) (k, q) and AP2 (anti-αIIbβ3 antibody) (a; g;
m), TEG4-2c scFv specifically recognizes the injured areas of the aorta sections from different species (c; i; o). Binding of antibodies
was visualized via HRP-anti-6His (scFv); HRP anti-rabbit IgG (CD41) and HRP anti-mouse IgG (RAM11, AP2). Negative controls were
secondary antibody only (b; d; f; h; j; l; n; p; r). Nuclei were counterstained with hematoxylin B: ELISA tests on atheromatous and
healthy aorta proteins: TEG4-2c shows a better recognition of atheromatous proteins. RAM11 and AP2 were used as positive controls.
Negative controls were secondary antibody only. Binding of antibodies was visualized via HRP-6His or HRP-anti-mouse IgG. OD value
represents absorbance at 450 nm. Values represent mean (n = 3) ± SD (error bars materialized the SD)
doi:10.1371/journal.pone.0170305.g006
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Discussion & Conclusion
In the present study, TEG4-2c scFv was expressed at high-level in Pichia pastoris using a fed-
batch fermentation system monitored by pO2 level. We produced the TEG4 scFv with cysteine
tags at the end of the C-terminal sequence for site-specific conjugation to contrast agents, pre-
cluding the loss of reactivity potentially occurring when the grafting process affects antigen-
recognition sites. TEG4 scFv had been previously expressed in E coli.[27] Unfortunately,
despite optimization tests leading to high yields of cytoplasmic production, proteins also fre-
quently accumulated into inclusion bodies (data not shown). In bacterial systems, many scFv
can be produced into the periplasmic space but they are obtained with a very low yield. Higher
levels of production can be achieved in inclusion bodies, with the limitation of the presence of
insoluble scFv aggregates and the need for subsequent in vitro folding that make the use of this
bacterial system not attractive for the large scale production of scFv. In addition, many authors
have described that the final yield of scFv was only a small percentage of produced proteins
with a low specificity for targets.[33,34]
So we chose to use the Pichia yeast as an alternative expression system. Indeed, Pichia pas-
toris is an attractive system for low cost-effective large-scale production of heterologous pro-
teins. This type of production, characterized by the secretion of the protein of interest into the
culture medium, can be easily scaled up and reach a GRAS (Generally Recognized As Safe) sta-
tus. The concentration of highly pure TEG4-2c scFv obtained after one chromatography step
(IMAC) was up to 600 μg/mL. A production of 30 mg scFv per liter of culture was achieved.
This value was lower than that obtained for an scFv anti-carcinoembryonic antigen,[33] but in
accordance with the yields obtained for the majority of Fab and antibody fragments expressed
in P. pastoris [35–37] and sufficient for grafting purposes.
This new scFv format with cysteines included for grafting purposes was tested by ELISA,
cytometry and IHC and all the experiments concurred to a specific recognition of platelets,
from human or animal model origin and of atheroma issuing from coronary biopsies or ani-
mal lesional tissues. Bio-layer interferometry was used for evaluating the affinity of TEG4-2c
scFv against platelets because this approach is more relevant than SPR analysis on purified
antigen to mimic the in vivo behavior. No real Kd value could be extracted from the curves
because of an absence of dissociation. This could be explained by the rebinding of the same
platelet on the immobilized ligand because of the presence of 50 000 αIIbβ3 per platelet.
Indeed, when the platelet is captured on the surface, one αIIbβ3 can dissociate while another
re-binds on the scFv. As a consequence the off-rate is slower than it would be by using isolated
αIIbβ3. Nevertheless, the bio-layer interferometry underlines a good affinity of TEG4-2c scFv
for platelets with recognition in the nanomolar range. Moreover, the flow cytometry results
with PRP are in favor of a preferential recognition of activated platelets. This approach, com-
pared to ELISA assays or cytometry performed on washed platelets is the only one that allows
recognition in physiological conditions.
The rationale for targeting activated platelets is that they are highly trapped within athero-
sclerotic lesions not only in thrombi and intraplaque hemorrhage but also in the atheroma
burden, around necrotic areas and neovessels, mainly because of the presence of leaky vessels,
blood extravasation and haemorrhage.[18] Preferential recognition of activated platelets is to
be considered to avoid in vivo elimination of the probe by circulating resting platelets.
An important point to be underlined is that scFv TEG4-2c recognizes human platelets as
well as murine or rabbit platelets. The use of a human antibody able to target epitopes on the
integrin shared by animal models and humans is of particular interest for pre-clinical studies
in animal models of the disease and for direct transfer into the clinic. The use of an antibody
of human origin is appealing, considering the need for repeated injections in humans to follow
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the progression of the pathology. Indeed, the human scFv should limit the induction of anti-
antibodies in patients as compared with murine origin; it also avoids any additional humaniza-
tion step that could impair the reactivity. This antibody equipped with cysteine tags is now
ready to be used to functionalize contrast agents for MRI to serve as imaging agents for
atherosclerosis.
In conclusion, even if the production of antibody fragments by P. pastoris is not always a
success story,[38] our findings demonstrated that P. pastoris provided TEG4-2c scFv at a high
concentration without aggregates and claiming a good purity. Its functionality against acti-
vated platelets and atheroma tissues was proven, paving the way for the success of grafting
tests. Our results definitely point out the P. pastoris expression system as an adapted tool to
produce scFv for use in diagnostic or therapeutic applications as well.
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